High-dose immunoglobulin therapy for steroid-resistant myositis in juvenile localized scleroderma.

Abstract

Juvenile localized scleroderma (jLS) is an autoimmune disease characterized by a mixture of inflammation and fibrosis on the skin and other underlying tissues.1 It often involves the muscles and joints, thus leading to serious problems in growth and motor dysfunctions during childhood. Recently, novel targeted drugs have been introduced for the treatment of jLS; however, these therapeutic options, apart from methotrexate (MTX) and corticosteroids (CS), have limited evidence supporting their long-term safety and efficacy against refractory jLS.